4D Molecular Therapeutics, Inc. Common Stock

FDMTNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
13.63 USD
↘ 0.13 (0.95%)AT CLOSE (11:59 AM EDT)
13.64
↗ 0.01 (0.07%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
13.64
↗ 0.01 (0.07%)
🔴Market: CLOSED

Shares of 4D Molecular Therapeutics, Inc. Common Stock (FDMT) are trading at $13.65. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. Notable factors include a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place FDMT at a fair price relative to peers.

Technical & fundamental data as of Sep 15, 2026.

Open?$13.95
High?$13.95
Low?$13.18
Prev. Close?$13.76
Volume?552.0K
Avg. Volume?939.7K
VWAP?$13.45
Rel. Volume?0.59x
Bid / Ask
Bid?$11.18 × 100
Ask?$17.56 × 100
Spread?$6.38
Midpoint?$14.37
Valuation & Ratios
Market Cap?760.2M
Shares Out?55.2M
Float?44.5M
Float %?85.2%
P/E Ratio?N/A
P/B Ratio?1.86
EPS?-$3.24
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Clinical-Stage Platforms
Employees
196
Market Cap
760.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.4dmoleculartherapeutics.com
Listed
2020-12-11
Address
5858 HORTON STREET #455
EMERYVILLE, CA 94608
Phone: (510) 505-2680
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
58
Momentum?
48
Short Sent.?
36
Piotroski F-Score?1/9Weak
Altman Z-Score?2.61Grey
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.10%Squeeze Risk
Short Interest?12.1M
Days to Cover?8.2
Free Float44.5M
Avg Daily Volume1.5M
Settlement Date2026-08-31
Financial Health
Current Ratio?8.03Strong
Quick Ratio?8.03Strong
Cash Ratio?1.48Strong
Debt/Equity?0.05Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
78
1.86CHEAP▾
P/S?
Peers
100
S&P
12
8.26HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.7CHEAP▾
EV/Sales?
Peers
100
S&P
18
7.71HIGH▾
Returns & Efficiency
ROE?
S&P
3
-44.0%WEAK▾
ROA?
S&P
3
-36.4%WEAK▾
Cash Flow & Enterprise
FCF?$-156177000
Enterprise Value?$709.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist